Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension 2018-06-15T21:13:04+00:00

Clinical Trials

June 15, 2018

Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension

  • Study Sponsor: Complexa, Inc.
  • Institution: Complexa, Inc.
  • Start Date: Friday, June 1, 2018
  • End Date: Tuesday, October 15, 2019
  • Design: 
    • Placebo-controlled
    • Background treatment allowed
  • Age range (years): 18 to 80
  • Type of PH
    • All PAH (Group 1 PH)
    • IPAH
    • Heritable – APAH
    • CTD – APAH
    • CHD – APAH
    • Toxic – APAH
    • HIV – APAH
  • Study Duration for individual patient: 20 weeks
  • Contact: www.complexarx.com/pipeline
  • Listing on clinicaltrials.gov